Erleada is an androgen receptor inhibitor used for the treatment of patients with
- metastatic castration-sensitive prostate cancer (mCSPC).
- non-metastatic castration-resistant prostate cancer (nmCRPC).
Recommended Dosage: The recommended dosage of Erleada tablets is 240 mg (4 × 60 mg tablets) administered orally (by mouth) once daily. Take these tablets with or without food. Each tablet of Erleada should be swallowed whole.
Gonadotropin-releasing hormone (GnRH) analog can be received concurrently or patients should have had a bilateral orchiectomy.
In case of a greater than or equal to Grade-3 toxicity or an intolerable adverse reaction, hold dosing with Erleada until signs/symptoms improve to less than or equal to Grade-1 or original grade, then resume at the same dose or a decreased dose (180 mg or 120 mg), if warranted.
In the event of a missed daily dose, patients should take their normal Erleada dose as quickly as possible on the same day with a return to the normal schedule on the following day. Do not take extra pills to make up for the missed or skipped dose.